We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+10.05%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$206M
AUM Growth
+$19.9M
Cap. Flow
-$6.78M
Cap. Flow %
-3.3%
Top 10 Hldgs %
45.09%
Holding
85
New
12
Increased
15
Reduced
25
Closed
10

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$11.1M
2
STXS icon
Stereotaxis
STXS
+$8.18M
3
AKBA icon
Akebia Therapeutics
AKBA
+$6.64M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$4.93M
5
LMNX
Luminex Corp
LMNX
+$4.14M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$12.2M
2
ONC
BeOne Medicines Ltd
ONC
+$7.32M
3
ARGX icon
argenx
ARGX
+$2.81M
4
VYGR icon
Voyager Therapeutics
VYGR
+$2.61M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 86.28%
2 Financials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCPH
51
DELISTED
scPharmaceuticals
SCPH
$692K 0.34%
55,844
-42,256
-43% -$568K
MTVA
52
MetaVia Inc
MTVA
$7.64M
$651K 0.32%
+2
New +$1.01M
DERM
53
DELISTED
Dermira, Inc.
DERM
$607K 0.3%
76,000
-10,000
-12% -$218K
LCTX icon
54
Lineage Cell Therapeutics
LCTX
$277M
$489K 0.24%
207,569
-106,756
-34% -$250K
MASI
55
DELISTED
Masimo
MASI
$440K 0.21%
5,000
– –
SPRO icon
56
Spero Therapeutics
SPRO
$66.6M
$421K 0.2%
29,544
+24,544
+491% +$298K
SLGL icon
57
Sol-Gel Technologies
SLGL
$268M
$361K 0.18%
+3,500
New +$392K
TNDM icon
58
Tandem Diabetes Care
TNDM
$1.38B
$298K 0.15%
+60,000
New +$193K
NEOS
59
DELISTED
Neos Therapeutics, Inc
NEOS
$228K 0.11%
27,500
– –
URGN icon
60
UroGen Pharma
URGN
$1.88B
$224K 0.11%
+4,500
New +$225K
SRRA
61
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$166K 0.08%
+1,999
New +$227K
RCUS icon
62
Arcus Biosciences
RCUS
$3.47B
$116K 0.06%
+7,500
New +$125K
CDTX
63
DELISTED
Cidara Therapeutics
CDTX
$93K 0.05%
1,157
-9,663
-89% -$1.32M
OBSV
64
DELISTED
ObsEva SA Ordinary Shares
OBSV
$92K 0.04%
6,785
-7,440
-52% -$91.3K
COGT icon
65
Cogent Biosciences
COGT
$6.64B
$88K 0.04%
+1,975
New +$87.8K
CLSD
66
DELISTED
Clearside Biomedical
CLSD
$54K 0.03%
+333
New +$40.6K
SCNI
67
Scinai Immunotherapeutics
SCNI
$1.41M
$18K 0.01%
+34
New +$21.2K
BLUE
68
DELISTED
bluebird bio
BLUE
– –
-154
Closed -$356K
PDSB icon
69
PDS Biotechnology
PDSB
$40M
– –
-970
Closed -$182K
RDHL
70
Redhill Biopharma
RDHL
$3.95M
– –
-35
Closed -$180K
SYRE icon
71
Spyre Therapeutics
SYRE
$8.24B
– –
-13,984
Closed -$1.89M
VYGR icon
72
Voyager Therapeutics
VYGR
$181M
– –
-157,000
Closed -$2.61M
DCPH
73
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-9,619
Closed -$218K
BLCM
74
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-2,000
Closed -$168K
RDUS
75
DELISTED
Radius Health, Inc.
RDUS
– –
-53,309
Closed -$1.69M
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, DAFNA Capital Management held 85 positions worth $206M, up 11% from $186M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

DAFNA Capital Management withdrew a net $6.78M in Q1 2018, closing 10 positions and reducing 25 holdings. Its most notable exit was Voyager Therapeutics, an estimated $2.61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 83% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Arena Pharmaceuticals Inc worth $5.01M.

  • DAFNA Capital Management's largest Q1 2018 buy was Arena Pharmaceuticals Inc: 126,742 shares worth $5.01M.
  • DAFNA Capital Management added most to Sage Therapeutics in Q1 2018, an estimated $11.1M increase.
  • DAFNA Capital Management's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $12.2M.
  • DAFNA Capital Management fully exited Voyager Therapeutics in Q1 2018, selling an estimated $2.61M.
  • DAFNA Capital Management's ten largest holdings make up 45% of its $206M portfolio in Q1 2018.
  • DAFNA Capital Management opened 12 new positions and closed 10 in Q1 2018.
  • DAFNA Capital Management's portfolio value rose 11% quarter-over-quarter to $206M.

Based on DAFNA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.